Non-Melanoma Skin Cancer

Non-Melanoma Skin Cancer

Global Non-Melanoma Skin Cancer Market to Reach $921.3 Million by 2030
In the changed post COVID-19 business landscape, the global market for Non-Melanoma Skin Cancer estimated at US$650.7 Million in the year 2022, is projected to reach a revised size of US$921.3 Million by 2030, growing at aCAGR of 4.4% over the period 2022-2030. Basal Cell Carcinoma (BCC), one of the segments analyzed in the report, is projected to record 4.7% CAGR and reach US$750.6 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Other Indications segment is readjusted to a revised 3.2% CAGR for the next 8-year period.

The U.S. Market is Estimated at $194.4 Million, While China is Forecast to Grow at 4.1% CAGR
The Non-Melanoma Skin Cancer market in the U.S. is estimated at US$194.4 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$161.4 Million by the year 2030 trailing a CAGR of 4.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 3.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Select Competitors (Total 46 Featured) -
  • Accuray, Inc.
  • Almirall S.A.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Elekta AB
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • iCAD, Inc.
  • Ion Beam Applications SA
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Sensus Healthcare
  • Sun Pharmaceutical Industries Ltd.
  • Varian Medical Systems, Inc.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Non-melanoma Skin Cancer – Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Non-Melanoma Skin Cancer Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
TABLE 3: World Historic Review for Non-Melanoma Skin Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 4: World 16-Year Perspective for Non-Melanoma Skin Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Basal Cell Carcinoma (BCC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
TABLE 6: World Historic Review for Basal Cell Carcinoma (BCC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 7: World 16-Year Perspective for Basal Cell Carcinoma (BCC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
TABLE 9: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 10: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
TABLE 12: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 13: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
TABLE 15: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 16: World 16-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
UNITED STATES
Non-Melanoma Skin Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
TABLE 17: USA Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
TABLE 18: USA Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 19: USA 16-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2014, 2023 & 2030
TABLE 20: USA Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
TABLE 21: USA Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 22: USA 16-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
CANADA
TABLE 23: Canada Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
TABLE 24: Canada Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 25: Canada 16-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2014, 2023 & 2030
TABLE 26: Canada Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
TABLE 27: Canada Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 28: Canada 16-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
JAPAN
Non-Melanoma Skin Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
TABLE 29: Japan Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
TABLE 30: Japan Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 31: Japan 16-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2014, 2023 & 2030
TABLE 32: Japan Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
TABLE 33: Japan Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 34: Japan 16-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
CHINA
Non-Melanoma Skin Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
TABLE 35: China Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
TABLE 36: China Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 37: China 16-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2014, 2023 & 2030
TABLE 38: China Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
TABLE 39: China Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 40: China 16-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
EUROPE
Non-Melanoma Skin Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
TABLE 41: Europe Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
TABLE 42: Europe Historic Review for Non-Melanoma Skin Cancer by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 43: Europe 16-Year Perspective for Non-Melanoma Skin Cancer by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
TABLE 44: Europe Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
TABLE 45: Europe Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 46: Europe 16-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2014, 2023 & 2030
TABLE 47: Europe Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
TABLE 48: Europe Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 49: Europe 16-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
FRANCE
Non-Melanoma Skin Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
TABLE 50: France Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
TABLE 51: France Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 52: France 16-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2014, 2023 & 2030
TABLE 53: France Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
TABLE 54: France Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 55: France 16-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
GERMANY
Non-Melanoma Skin Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
TABLE 56: Germany Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
TABLE 57: Germany Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 58: Germany 16-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2014, 2023 & 2030
TABLE 59: Germany Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
TABLE 60: Germany Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 61: Germany 16-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
ITALY
TABLE 62: Italy Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
TABLE 63: Italy Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 64: Italy 16-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2014, 2023 & 2030
TABLE 65: Italy Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
TABLE 66: Italy Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 67: Italy 16-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
UNITED KINGDOM
Non-Melanoma Skin Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
TABLE 68: UK Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
TABLE 69: UK Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 70: UK 16-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2014, 2023 & 2030
TABLE 71: UK Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
TABLE 72: UK Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 73: UK 16-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
REST OF EUROPE
TABLE 74: Rest of Europe Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
TABLE 75: Rest of Europe Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 76: Rest of Europe 16-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2014, 2023 & 2030
TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
TABLE 78: Rest of Europe Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 79: Rest of Europe 16-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
ASIA-PACIFIC
Non-Melanoma Skin Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
TABLE 80: Asia-Pacific Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
TABLE 81: Asia-Pacific Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 82: Asia-Pacific 16-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2014, 2023 & 2030
TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
TABLE 84: Asia-Pacific Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 85: Asia-Pacific 16-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
REST OF WORLD
TABLE 86: Rest of World Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
TABLE 87: Rest of World Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 88: Rest of World 16-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2014, 2023 & 2030
TABLE 89: Rest of World Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
TABLE 90: Rest of World Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
TABLE 91: Rest of World 16-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2014, 2023 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings